1. United Kingdom Stocks

  2. •

    Financial Services

  3. •

    Shell Companies
In Veritas Medical Diagnostics, Inc.

In Veritas Medical Diagnostics, Inc.

IVMED
In Veritas Medical Diagnostics, Inc.US flagOther OTC
0.00
USD
- -
- -
120.00Market Cap
In Veritas Medical Diagnostics, Inc.
IVMED
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2003
2004
2005
2006
2007
TTM
FRC
- -
32.05
8.37
11.54
- -
- -
Revenue per Share
-0.42
-42.86
-23.32
-16.78
-31.03
-25.95
Basic EPS, GAAP
-0.06
-34.23
-7.21
-6.18
-6.74
-3.47
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
-1.93
-111.95
-65.21
-78.72
-104.32
-112.84
Book Value per Share
-0.18
-96.38
-27.25
-42.93
-60.34
-67.76
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
1
1
1
- -
- -
Sales/Revenue/Turnover
-5,736.26
-133.72
-257.52
-75.45
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-2
-2
-4
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-8,945.26
-133.72
-278.55
-145.45
- -
- -
Profit Margin (%)
- -
-2
-1
-2
-6
-7
Working Capital
- -
- -
2
2
1
1
LT Debt
- -
-2
-3
-5
-7
-8
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jul'07
Oct'08
Jan'08
ST Debt
3
3
4
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jul'07
Oct'08
Jan'08
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
7
7
Payables & Accruals
3
3
3
ST Debt
3
3
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
52.44%
Free Cash Flow
- -
- -
17.02%
Net Income, GAAP
- -
- -
98.55%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
1
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-2.57
-2.77
-2.78
- -
-16.78
2007
-7.59
-8.31
-5.77
- -
-31.03
2008
-5.44
-5.17
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -
Similar Companies
Arogo Capital Acquisition Corp. (AOGO)
LightJump Acquisition Corporation (LJAQU)
Vado Corp. (VADP)
Liberty Resources Acquisition Corp. (LIBYW)
Green Hygienics, Inc. (GRHY)
EF Hutton Acquisition Corporation I Warrant (EFHTW)
Business
In Veritas Medical Diagnostics, Inc. (IVMED), now operating as Whitebeard Inc., functions as a shell company with no active business operations or revenue generation; it provides no medical diagnostics products or services, including any prothrombin monitors historically referenced in profiles. The company maintains a minimal staff of eight employees and focuses solely on its holding structure without core offerings in diagnostic equipment, reagents, or related healthcare technologies. Headquartered at 1 Temple Avenue, Temple Hamilton House, London EC4Y 0HA, United Kingdom, it was incorporated prior to its current non-operational status, with no specified founding year for diagnostics activities. Leadership includes CEO David Ajemian and CFO Martin Thorp, alongside a board featuring Ajemian as director. Recent changes encompass a name transition to Whitebeard Inc., an extraordinary stock price surge exceeding 299,900% year-to-date to $150 per share, and reclassification under investment holding companies on OTC Markets, signaling potential restructuring or merger pursuits without disclosed partnerships, funding, acquisitions, or operational expansions. The associated whitebeard.ai domain hosts unrelated AI-powered B-book risk management technology for FX/CFD brokers via "The Pawn" neural network system, but no integration or affiliation with IVMED's shell entity appears in public records.